🔥Join us at the next ESMO Virtual Plenary session❗️

👉Is there a new PARPi option for HER2-neg gBRCA1/2mut MBC?
👉 Does a combination of PARPi and antiangiogenic drug (apatinib) improve efficacy?
👉Are VEGFRi better than bevacizumab?

ESMO - Eur. Oncology
Evandro de Azambuja, MD, PhD

#ESMOVirtualPlenary : Tune in tomorrow (9/5) for the latest, promising findings for the treatment of metastatic #breastcancer (mBC). Open to everyone, everywhere. 📢 Fuzuloparib w/ or without apatinib in HER2- mBC pts w/ germline BRCA1/2 mutations: A randomised ph III trial.…

#ESMO24 : 📣Last 24 hours to submit. Watch Andres Cervantes, Rebecca Dent, Karin Jordan, Chris Verslype, Ann Partridge MD, MPH and Petros Grivas give excellent reasons to share your research. Deadline: 7 May 2024.

esmo.org/meeting-calend…

Congrats Eileen Poon Evelyn Wong Jianbang Chiang & other colleagues at Duke-NUS Medical School #NCCS for hosting a comprehensive 2day symposium on #AYAOncology . Need to #collectively #push this agenda forward. Plenty of room for collaborations in the #APAC region. Thanks for the invite!…

Great work Eileen Poon Evelyn Wong and team. Putting together a collection of physicians across Asia dedicated in the AYA(adult and young adolescents) group to improve cancer care in this group of patients. Important conversations starting here. Onwards and upwards!

Such an important question addressed in the Alliance A011502 study looking at adjuvant aspirin in breast cancer found no benefit.

Wonderful work by Wendy Chen and the Alliance team!

Dana-Farber’s Breast Oncology Center

⚡️ Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer

jamanetwork.com/journals/jama/…

#BreastCancer Roberto Leon-Ferre Carmen Criscitiello Vincent Cockenpot Matteo Lambertini, MD PhD Shu Yazaki, MD, PhD Maria Vittoria Dieci Anne Vincent-Salomon FabriceAndre MarleenKokLab Matthew Goetz Stefan Michiels Sherene Loi, MD Dra. María Natalia Gandur Quiroga Alizée Camps - - Maléa…

Singapore Translational Cancer Consortium & Mount Sinai Hospital joining the IMCORE cancer research collaboration of 27 cancer centres & Roche. 96 cancer research project with >2000 scientists/HCPs and many high impact publications.Asian expansion reflects the global network

New report on the risk of radiation necrosis with concurrent ADCs + brain RT. Incidence of symptomatic radiation necrosis was 27% with concurrent vs. 11% with non-concurrent ADC/RT (p=0.014). Important to temporarily stop the ADC before pursuing brain RT. link.springer.com/article/10.100…

Myriam Chalabi Toni Choueiri, MD ESMO - Eur. Oncology Andres Cervantes Rachel Riechelmann Vivek Subbiah, MD Sumanta K. Pal, MD, FASCO Solange Peters MarleenKokLab Jakob Nikolas Kather Elena Elez The Netherlands Cancer Institute Congrats! Looking forward to an exciting ESMO this year! We will not disappoint in #LCSM Benjamin Besse Rebecca Dent x

Nerea Lopetegui-Lia, MD Join us tonight❗️Daniel Stover, MD, FASCO Nicole Williams MD Sagar Sardesai Dionisia Quiroga, DO, PhD Arya Roy Stephanie Graff, MD, FACP, FASCO Tatiana Prowell, MD Jennifer Gao Sara Tolaney Paolo Tarantino Rebecca Shatsky, MD Rebecca Dent Heather McArthur, MD, MPH Hope Rugo @gulleyj1 Shipra Gandhi Zihai Li, MD, PhD Aditya Bardia, MD Prarthna Bhardwaj Elad Sharon

Indeed! And trials for TNBC should allow ER low pts! Highly likely that these pts will benefit from IO as well as suggested by KN756 and CM7FL #bcsm OncoAlert

#ESMO24 : Just under 1 month left to share your research 📣 Discuss your findings with international, like-minded professionals who are shaping the future of #CancerPatient care. ⏲️ Submit your abstract by 7 May 2024. ow.ly/X51l50RcStY

Andres Cervantes Rebecca Dent

Last day to submit your abstracts to #ASCOBT24 !!

Lots of research awards for the top40 ranked abstracts and also Merit awards for trainees!

Junior faculty and trainees opportunities are also being lined up 😊

ASCO ASCOPres Lillian Siu

#ESMO24 : A place to share your research, explore promising areas of development and engage with the international #oncology community. 📣 Submit your abstract by ⏲️ 7 May 2024.
ow.ly/NYB450QEXU1

Andres Cervantes Rebecca Dent

Absolutely!

Call me biased but would love to see Lillian Siu be the next AACR president-elect!

Vote!!!

Missed it live? No worries! The SPCC and ABC Global Alliance webinar 'Highlights from ABC7 International Consensus Conference' is now available on demand for free! Catch up on all the insightful discussions at your convenience. 🌟🎥 oncocorner.net/index.php?p=ev…

The #ESMO24 registration system is now open 📢 Play your part in this highly influential, multidisciplinary #oncology platform for clinicians, researchers and advocates. ⏲️ Register by 12 June and benefit from the most advantageous rates. ow.ly/leBP50QG6Hw
#MedTwitter …

The #ESMO24 abstract submission system is now open…looking forward to another great ESMO - Eur. Oncology annual congress with important science and news for our patients!

OncoAlert Università di Genova Ospedale San Martino Genova #ESMOYOC Andres Cervantes Rebecca Dent FabriceAndre

KEYNOTE-522 outcomes by RCB out on Annals of Oncology. Largest benefit from pembro was observed in the RCB-2 group. Striking difference in 3-year EFS between RCB-1 (≃84%) and RCB-3 (≃30%): not all residual disease is created equal! annalsofoncology.org/article/S0923-…